• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Quadruple Medical Therapy for Heart Failure: Medications Working Together to Provide the Best Care.

作者信息

Greene Stephen J, Khan Muhammad Shahzeb

机构信息

Duke Clinical Research Institute, Durham, North Carolina, USA; Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA.

Department of Medicine, University of Mississippi, Jackson, Mississippi, USA.

出版信息

J Am Coll Cardiol. 2021 Mar 23;77(11):1408-1411. doi: 10.1016/j.jacc.2021.02.006.

DOI:10.1016/j.jacc.2021.02.006
PMID:33736822
Abstract
摘要

相似文献

1
Quadruple Medical Therapy for Heart Failure: Medications Working Together to Provide the Best Care.心力衰竭的四联药物疗法：药物协同作用以提供最佳治疗。
J Am Coll Cardiol. 2021 Mar 23;77(11):1408-1411. doi: 10.1016/j.jacc.2021.02.006.
2
Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?2型糖尿病中的钠-葡萄糖协同转运蛋白2抑制剂：一种降低心力衰竭的神奇药物？
Expert Rev Clin Pharmacol. 2019 Aug;12(8):693-695. doi: 10.1080/17512433.2019.1635453. Epub 2019 Jun 30.
3
The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.钠-葡萄糖共转运蛋白 2 抑制剂在心力衰竭患者中的作用，无论糖尿病状态如何：关注心血管疾病。
Ann Pharmacother. 2021 Oct;55(10):1267-1275. doi: 10.1177/1060028020985111. Epub 2021 Jan 5.
4
Meta-Analysis of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure Patients Without Diabetes.非糖尿病心力衰竭患者中钠-葡萄糖协同转运蛋白2抑制剂的荟萃分析
Am J Cardiol. 2021 Jun 1;148:175-176. doi: 10.1016/j.amjcard.2021.03.001. Epub 2021 Mar 6.
5
The Sweet Spot: Heart Failure Prevention with SGLT2 Inhibitors.甜蜜点：SGLT2 抑制剂预防心力衰竭。
Am J Med. 2020 Feb;133(2):182-185. doi: 10.1016/j.amjmed.2019.08.013. Epub 2019 Sep 5.
6
Sodium-glucose cotransporter 2 inhibitors and heart failure decompensation: considerations on body composition and skeletal mass.
Pol Arch Intern Med. 2021 Dec 22;131(12). doi: 10.20452/pamw.16168.
7
Treatment of heart failure with sodium glucose co-transporter-2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions.钠-葡萄糖共转运蛋白 2 抑制剂治疗 2 型糖尿病心力衰竭患者：当前证据与未来方向。
Diabet Med. 2019 Dec;36(12):1550-1561. doi: 10.1111/dme.14140. Epub 2019 Oct 10.
8
Sodium-glucose cotransporter 2 inhibitors and heart failure decompensation: considerations on body composition and skeletal mass. Authors' reply.钠-葡萄糖协同转运蛋白2抑制剂与心力衰竭失代偿：关于身体成分和骨骼质量的考量。作者回复
Pol Arch Intern Med. 2021 Dec 22;131(12). doi: 10.20452/pamw.16169.
9
Letter by Koh Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".科关于文章《钠-葡萄糖协同转运蛋白2抑制剂起始治疗患者与其他降糖药物相比心力衰竭和死亡风险更低：CVD-REAL研究（钠-葡萄糖协同转运蛋白2抑制剂新使用者心血管结局的比较有效性）》的信
Circulation. 2018 Feb 27;137(9):984-985. doi: 10.1161/CIRCULATIONAHA.117.030650.
10
Letter by Taegtmeyer and Karlstaedt Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".泰格特迈尔和卡尔施泰特就文章《钠-葡萄糖协同转运蛋白2抑制剂起始治疗患者与其他降糖药物相比心力衰竭和死亡风险更低：CVD-REAL研究（钠-葡萄糖协同转运蛋白2抑制剂新使用者心血管结局的比较有效性）》所写的信
Circulation. 2018 Feb 27;137(9):986-987. doi: 10.1161/CIRCULATIONAHA.117.031193.

引用本文的文献

1
Impact of a structured educational intervention on attitudes and practice of heart failure in Latin America.结构化教育干预对拉丁美洲心力衰竭态度和实践的影响。
Arch Cardiol Mex. 2025;95(3):169-174. doi: 10.24875/ACM.24000111.
2
Guideline-Directed Medical Therapy After Hospitalization for Acute Heart Failure: Insights From the CONNECT-HF.急性心力衰竭住院后的指南导向性药物治疗：来自CONNECT-HF研究的见解
J Am Heart Assoc. 2024 Dec 17;13(24):e036998. doi: 10.1161/JAHA.124.036998. Epub 2024 Dec 10.
3
Examination of the Suitability of Vericiguat in Non-Heart Failure with Preserved Ejection Fraction Patients with Improved Ejection Fraction.
维立西呱在射血分数改善的非心力衰竭且射血分数保留患者中的适用性研究。
J Clin Med. 2024 Sep 5;13(17):5264. doi: 10.3390/jcm13175264.
4
Genetic drivers of human plasma metabolites that determine mortality in heart failure patients with reduced ejection fraction.射血分数降低的心力衰竭患者中决定死亡率的人体血浆代谢物的遗传驱动因素。
Front Cardiovasc Med. 2024 Jul 9;11:1409340. doi: 10.3389/fcvm.2024.1409340. eCollection 2024.
5
Inflammation in Heart Failure-Future Perspectives.心力衰竭中的炎症——未来展望
J Clin Med. 2023 Dec 17;12(24):7738. doi: 10.3390/jcm12247738.
6
Clinical Profile, Health Care Costs, and Outcomes of Patients Hospitalized for Heart Failure With Severely Reduced Ejection Fraction.患有严重射血分数降低的心力衰竭患者的临床特征、医疗费用和结局。
J Am Heart Assoc. 2023 May 16;12(10):e028820. doi: 10.1161/JAHA.122.028820. Epub 2023 May 9.
7
Medication-Attributable Adverse Events in Heart Failure Trials.心力衰竭试验中的药物相关不良事件
JACC Heart Fail. 2023 Apr;11(4):425-436. doi: 10.1016/j.jchf.2022.11.026. Epub 2023 Feb 1.
8
Insights into foundational therapies for heart failure with reduced ejection fraction.射血分数降低型心力衰竭的基础治疗新视角。
Clin Cardiol. 2022 Jun;45 Suppl 1(Suppl 1):S26-S30. doi: 10.1002/clc.23847.
9
Evolving therapeutic strategies for patients hospitalized with new or worsening heart failure across the spectrum of left ventricular ejection fraction.针对左心室射血分数不同阶段的新发或恶化心力衰竭住院患者的治疗策略不断演变。
Clin Cardiol. 2022 Jun;45 Suppl 1(Suppl 1):S40-S51. doi: 10.1002/clc.23849.
10
Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis.2 型糖尿病患者心力衰竭住院的临床预测模型：系统评价和荟萃分析。
J Am Heart Assoc. 2022 May 17;11(10):e024833. doi: 10.1161/JAHA.121.024833. Epub 2022 May 16.